DB
KURA icon

Dmitry Balyasny’s Kura Oncology KURA Stock Holding History

Dmitry Balyasny’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-86,798
Closed -$768K – 3339
2025
Q3 		$768K Sell
86,798
-48,849
-36% -$348K ﹤0.01% 2227
2025
Q2 		$783K Buy
+135,647
New +$831K ﹤0.01% 2138
2025
Q1 		– Sell
-16,485
Closed -$144K – 3059
2024
Q4 		$144K Sell
16,485
-17,312
-51% -$249K ﹤0.01% 2571
2024
Q3 		$660K Buy
+33,797
New +$685K ﹤0.01% 2146
2024
Q1 		– Sell
-25,527
Closed -$367K – 2887
2023
Q4 		$367K Sell
25,527
-21,338
-46% -$210K ﹤0.01% 2084
2023
Q3 		$427K Buy
+46,865
New +$476K ﹤0.01% 1804
2023
Q2 		– Sell
-1,146,056
Closed -$14M – 2547
2023
Q1 		$14M Sell
1,146,056
-1,152,963
-50% -$14.4M 0.04% 648
2022
Q4 		$28.5M Buy
2,299,019
+407,534
+22% +$5.92M 0.08% 336
2022
Q3 		$25.8M Buy
1,891,485
+457,471
+32% +$7.06M 0.08% 338
2022
Q2 		$26.3M Buy
+1,434,014
New +$20.6M 0.09% 334

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Dmitry Balyasny's KURA Position: Q4 2025 in Review

Dmitry Balyasny sold out of Kura Oncology (KURA) in Q4 2025, closing a stake of 86,798 shares — an estimated $768K sold.

Dmitry Balyasny first reported a position in KURA in Q2 2022 and held it in 10 quarters. The position peaked at $28.5M in Q4 2022. 215 funds tracked by Wall St. Rank hold KURA as of Q4 2025.

  • Dmitry Balyasny reported no remaining Kura Oncology position as of Q4 2025 after selling out during the quarter.
  • Dmitry Balyasny sold 86,798 Kura Oncology shares in Q4 2025, an estimated $768K.
  • Dmitry Balyasny first reported a position in Kura Oncology in Q2 2022 and held it in 10 quarters.
  • Dmitry Balyasny's Kura Oncology position peaked at $28.5M in Q4 2022.
  • 215 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.